Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), filed a Form 4 on November 6, 2026, disclosing nine separate sales of common stock totaling 1,960 shares on November 5, 2026, executed under a pre-arranged 10b5-1 trading plan.
Key Highlights
- Total shares sold: 1,960 shares of United Therapeutics common stock disposed of on November 5, 2026, across nine transactions, all held indirectly by trust.
- Price range: Weighted average prices per transaction ranged from $593.1399 to $602.49, with individual trade prices spanning $592.58 to $602.96, according to the filing.
- 10b5-1 plan: All sales were made pursuant to a pre-arranged trading plan adopted by the reporting person on November 7, 2025, covering up to 1,734,410 stock options expiring March 15, 2027, and running until the earlier of full exercise or December 31, 2026.
- Remaining indirect beneficial ownership (trust): Following the reported transactions, 324,443 shares are held indirectly by the primary family trust referenced in the transactions.
- Direct holdings: The filing reports 40,513 shares held directly by the reporting person.
- Split filing: The filing notes it "is being filed across two forms" due to the 30-line table limitation, and this is identified as the second of two filings.
Rothblatt's November 5 Sales: Transaction Details and Ownership Summary
According to the Form 4 filing, Martine A. Rothblatt, serving as Chairperson and CEO of United Therapeutics Corp, disposed of a combined 1,960 shares of common stock on November 5, 2026. The shares were sold in nine separate tranches, each executed in multiple trades and reported at weighted average prices. Per the filing, individual transaction prices ranged from a low of $592.58 to a high of $602.96 across all trades that day.
The filing states that all nine sales were made pursuant to a pre-arranged trading plan adopted November 7, 2025, satisfying the affirmative defense conditions of Rule 10b5-1(c). That plan is set to continue until the earlier of the exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026. The shares sold were held indirectly through family trusts described as those "as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries."
Following all reported transactions, the filing shows Rothblatt's beneficial ownership across several categories: 40,513 shares held directly; 166 shares held indirectly by spouse; 249,108 shares in one category of family trust; 45,596 in another; and 8,902 in a third. The filing was signed by John S. Hess, Jr. under Power of Attorney on November 6, 2026, and notes it is the second of two forms filed to accommodate the 30-line table limitation.
What Was Disclosed
The filing reports nine sales of United Therapeutics common stock by CEO and Chairperson Martine A. Rothblatt on November 5, 2026, totaling 1,960 shares at weighted average prices between $593.1399 and $602.49, all conducted under a 10b5-1 plan adopted November 7, 2025.



Please wait processing your request...